Template:Pyrazinamide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | {| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Pyrazinamide|{{fontcolor|#6C7B8B|Pyrazinamide}}]]''''' | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background: | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | PYRAZINAMIDE<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]] | ||
| Line 19: | Line 17: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]] | ||
|- | |- | ||
|} | |} | ||